Electromed, Inc. reported a total revenue of $64 million for the fiscal year ending June 30, 2025, marking a 17% increase from $54.7 million in the previous fiscal year. The company's homecare revenue rose by 15.7% to $57.3 million, driven by an increase in direct sales representatives and higher net revenues per approval. Hospital revenue also saw a significant increase of 23.9%, reaching $3.1 million, while homecare distributor revenue surged by 58.1% to $2.9 million, attributed to a growing number of distribution partners. The overall gross profit increased to $50 million, representing 78.1% of net revenues, up from 76.3% in the prior year.

Electromed's operating income rose by 46.8% to $9.7 million, compared to $6.6 million in fiscal 2024. The increase in operating income was primarily due to higher net revenues and gross profit. However, selling, general, and administrative expenses also increased by 14% to $39.3 million, largely due to higher payroll and compensation-related expenses, which rose by 13.5% to $26.6 million. Research and development expenses increased significantly by 51.8% to $996,000, reflecting the company's commitment to product enhancements and sustaining engineering.

In terms of strategic developments, Electromed launched the SmartVest Clearway, a next-generation High Frequency Chest Wall Oscillation (HFCWO) system, in November 2022. This product is designed to enhance patient experience and improve treatment outcomes. The company continues to focus on expanding its sales force and increasing brand awareness, particularly in the adult pulmonology and bronchiectasis markets, which are identified as key growth areas. As of June 30, 2025, Electromed employed 180 individuals, including 55 direct field sales employees, and had established a network of approximately 176 respiratory therapists across the U.S. to assist with patient training.

Electromed's market position remains strong, with a significant opportunity in the U.S. homecare market for HFCWO, estimated at $245 million and growing at an 8% compound annual growth rate. The company believes that bronchiectasis represents the fastest-growing diagnostic category for HFCWO therapy, with a 12% annual growth rate. The SmartVest System is primarily prescribed for patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions, and the company is focused on generating clinical evidence to support its use in these populations.

Looking ahead, Electromed anticipates continued revenue growth driven by market share expansion and product innovation. The company is also mindful of potential challenges, including supply chain issues and inflationary pressures on component costs. Electromed's management believes that its current cash position, along with available borrowings under its credit facility, will provide sufficient liquidity to meet operational needs for at least the next twelve months.

About Electromed, Inc.

Electromed, Inc. develops, manufactures, and markets the SmartVest airway clearance system, primarily serving patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions. Its products use high-frequency chest wall oscillation (HFCWO) to improve respiratory function, reduce infections, and lower healthcare costs. The company employs a direct-to-patient and provider sales model, focusing on clinical evidence, reimbursement support, and product innovation in the U.S. and select international markets.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.